Service de Neurochirurgie, GHU Paris - Psychiatrie et Neurosciences - Hôpital Sainte-Anne, 1, rue Cabanis, 75674, Paris, France.
Université de Paris, Sorbonne Paris Cité, Paris, France.
Neurosurg Rev. 2022 Apr;45(2):1501-1511. doi: 10.1007/s10143-021-01670-7. Epub 2021 Oct 14.
Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect. An observational retrospective monocentric study was conducted including 122 consecutive adult patients with a newly diagnosed supratentorial glioblastoma who underwent a surgical resection with Carmustine wafer implantation as first line treatment (2005-2018). Twenty-two patients (18.0%) developed a postoperative contrast-enhancing cyst within the surgical bed: 16 surgical bed cysts and six bacterial abscesses. All patients with a surgical bed cyst were managed conservatively, all resolved on imaging follow-up, and no patient stopped the radiochemotherapy. Independent risk factors of formation of a postoperative surgical bed cyst were age ≥ 60 years (p = 0.019), number of Carmustine wafers implanted ≥ 8 (p = 0.040), and partial resection (p = 0.025). Compared to surgical bed cysts, the occurrence of a postoperative bacterial abscess requiring surgical management was associated more frequently with a shorter time to diagnosis from surgery (p = 0.009), new neurological deficit (p < 0.001), fever (p < 0.001), residual air in the cyst (p = 0.018), a cyst diameter greater than that of the initial tumor (p = 0.027), and increased mass effect and brain edema compared to early postoperative MRI (p = 0.024). Contrast enhancement (p = 0.473) and diffusion signal abnormalities (p = 0.471) did not differ between postoperative bacterial abscesses and surgical bed cysts. Clinical and imaging findings help discriminate between surgical bed cysts and bacterial abscesses following Carmustine wafer implantation. Surgical bed cysts can be managed conservatively. Individual risk factors will help tailor their steroid therapy and imaging follow-up.
卡莫司汀植入剂可用于高级别脑胶质瘤的手术部位,可能导致手术部位囊形成,从而导致有临床意义的肿块效应。本研究开展了一项观察性回顾性单中心研究,纳入了 122 例新诊断的幕上胶质母细胞瘤成人患者,这些患者接受了含卡莫司汀植入剂的手术切除,作为一线治疗(2005-2018 年)。22 例患者(18.0%)在手术部位形成了术后对比增强囊肿:16 例手术部位囊肿和 6 例细菌脓肿。所有手术部位囊肿患者均采用保守治疗,所有患者的影像学随访均得到解决,且没有患者停止放化疗。术后手术部位囊肿形成的独立危险因素为年龄≥60 岁(p=0.019)、植入卡莫司汀植入剂数量≥8 枚(p=0.040)和部分切除(p=0.025)。与手术部位囊肿相比,需要手术治疗的术后细菌脓肿发生与从手术到诊断的时间更短(p=0.009)、新的神经功能缺损(p<0.001)、发热(p<0.001)、囊内残留空气(p=0.018)、囊肿直径大于初始肿瘤直径(p=0.027)以及与术后早期 MRI 相比,肿块效应和脑水肿增加有关(p=0.024)。术后细菌脓肿和手术部位囊肿之间的对比增强(p=0.473)和弥散信号异常(p=0.471)无差异。临床和影像学表现有助于区分卡莫司汀植入术后手术部位囊肿和细菌脓肿。手术部位囊肿可以保守治疗。个体危险因素有助于制定类固醇治疗和影像学随访方案。